Rosetta Genomics AAQS 2025

Τι κάνει η Rosetta Genomics;

Rosetta Genomics Ltd is a company specializing in personalized medicine, focused on the development and commercialization of diagnostic tests based on RNA interference and NGS technologies for cancer diseases. The company was founded in 2000 and has its headquarters in Israel, with offices in the USA and Europe. The history of Rosetta Genomics began with the development of MicroRNA (miRNA), RNA molecules that act as regulators of gene expression in cells. The company developed a technology that allows for the identification of specific miRNAs that are characteristic of different types of cancers. As a result, Rosetta Genomics started developing a series of diagnostic tests based on these miRNAs to enable personalized therapy for cancer patients. Rosetta Genomics' business model is based on the commercialization of diagnostic tests for various cancer types. These tests can be requested by doctors and other medical professionals to determine the best treatment for patients. The company works closely with clinicians and researchers to continually improve its tests and stay up to date with the latest technology. The company operates in two main divisions: RosettaGX and RosettaWGX. RosettaGX offers diagnostic tests for various cancer types, including lung cancer, thyroid cancer, and colorectal cancer. These tests utilize Rosetta Genomics' proprietary RNA interference technology to identify specific miRNAs indicative of a particular type of cancer. On the other hand, RosettaWGX offers NGS services that allow researchers and pharmaceutical companies to collect and analyze DNA sequencing data to gain insights into the genetics of cancer. Some of the products offered by Rosetta Genomics include the miRview® Lung Test, miRview® mets2 Test, and miRview® Thyroid Test. The miRview® Lung Test identifies specific miRNAs characteristic of various types of lung tumors to enable an accurate diagnosis. The miRview® mets2 Test can determine the origin of cancer cells that have spread from the primary site, enabling targeted treatment. The miRview® Thyroid Test enables an accurate diagnosis of thyroid cancer and can determine the likelihood of a more aggressive form of the disease. Overall, Rosetta Genomics has developed a wide range of diagnostic tests and services based on a unique technology platform to enable personalized medicine for cancer patients. The company collaborates closely with doctors, researchers, and pharmaceutical companies to continually improve its tests and stay at the forefront of technology. With its innovative products and services, Rosetta Genomics is an important player in the field of personalized medicine and contributes to improving treatment outcomes for cancer patients. Rosetta Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.